First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma-Reference-Cited by-同舟云学术

First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma

Published:2024-07 Issue:7 Volume:49 Page:e334-e337
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Banihashemian Seyedeh Somayyeh¹,Bayat Mohadese²,Pirayesh Elahe²,Divband Ghasemali³,Abolhosseini Abdolghafar⁴,Akbari Mohammad Esmaeel¹

Affiliation:

1. Cancer Research Center, Shahid Beheshti University of Medical Sciences

2. Department of Nuclear Medicine, Shohada Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences

3. Khatam PET-CT Center, Khatam-al-Anbia Hospital

4. Parsisitope Company, Tehran, Iran.

Abstract

Abstract Fibroblast activation protein (FAP) is a new promising molecular target for theragnostic approach. FAP inhibitors (FAPIs) labeled with 177Lu could be potentially a therapeutic radiopharmaceutical. Here, we presented the experience of 4 cycles of 177Lu-FAPI in a 67-year-old man with an unresectable mediastinal sarcoma.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference10 articles.

1. Fibroblast activation protein in remodeling tissues;Curr Mol Med,2012

2. Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies;Int Rev Cell Mol Biol,2012

3. Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome;Clin Nucl Med,2022

4. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre) clinical studies;Eur J Nucl Med Mol Imaging,2023

5. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study;Thyroid,2022